Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Egyesült Államok1. fázis

T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies.

A legfontosabb adatok

Ki végzi
St. Jude Children's Research Hospital
Hol
Memphis (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
1. fázis
Résztvevők
32 fő, tervezett
Kezdés
2026. dec.
Várható befejezés
2034. dec.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Fludarabine
  • Cyclophosphamide
  • CliniMACS
  • Mesna
A regiszteradat frissítve
2026. november 17.

Ki vehet részt

Életkor
Legfeljebb 21 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 51 feltétel megnézéseKevesebb

Egyéb feltételek

  • Procurement and T-cell production Eligibility*
  • *a previously frozen, autologous leukapheresis product can be used for T-cell production Recipient Inclusion
  • Age ≤21 years old
  • Relapsed/refractory CD7+ AML; Relapsed disease: Patients developing recurrent disease after a prior complete remission (CR); Refractory disease: Patients with persistent disease despite 2 cycles of induction chemotherapy
  • Relapsed/refractory T-cell ALL/lymphoma; Relapsed disease: Patients developing recurrent disease after a prior complete remission (CR); Refractory disease: Patients with persistent disease despite 2 cycles of induction chemotherapy
  • Estimated life expectancy of >12 weeks
  • Karnofsky or Lansky (age-dependent) performance score ≥50
  • Patients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis
  • Patient must have an identified HCT donor
  • For females of childbearing age:; Not lactating with intent to breastfeed; Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment
  • For patients on Arm A: Meets eligibility criteria to undergo autologous apheresis, or have a previously frozen, autologous leukapheresis product that can be used for T-cell production
  • For patients on Arm B: Have an available donor that meets donor criteria; Recipient Exclusion
  • Known primary immunodeficiency
  • Known HIV positivity
  • Severe intercurrent bacterial, viral or fungal infection
  • History of hypersensitivity to cornstarch or hydroxyethyl starch
  • Patients with acute promyelocytic leukemia (APL)
  • Known contraindication to protocol defined lymphodepleting chemotherapy regimens of Fludarabine/cyclophosphamide
  • AML patients who failed FDA-approved targeted treatment options (e.g., FLT3 inhibitors, IDH1/IDH2 inhibitors, NPM1/KMT2A, CD33-directed.We define therapy failure as meeting one of the following; contraindications to receiving targeted therapy; or; toxicities that necessitate stopping the targeted therapy; or; progressive disease; Donor eligibility criteria for Arm B of the study: Apheresis and manufacturing
  • Recipient with relapsed CD7+ disease
  • Allogeneic donor either previous transplant donor for recipient, or haplo-identical donor if previous transplant donor is not available or autologous collection is not feasible in patients that have not had a previous transplant
  • HIV negative
  • For females of child bearing age:
  • Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND; o Not lactating with intent to breastfeed
  • Regarding donation eligibility, is identified as either:; Completed the process of donor eligibility determination as outlined in 21CFR 1271 and agency guidance; OR; Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271; This will follow standard allogeneic donor criteria per FDA mandate as defined in our allogeneic transplant studies Recipient Pre-Treatment Tests Eligibility (Arm B) Inclusion
  • Identified eligible study recipient with relapsed and/or refractory CD7-positive hematological malignancy Exclusion
  • None; Treatment Eligibility (Arm A and Arm B) Inclusion
  • Age ≤21 years old
  • Detectable CD7+disease
  • Estimated life expectancy of >8 weeks
  • Karnofsky or Lansky (age-dependent) performance score ≥ 50
  • Patients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion
  • Patient must have an identified HCT donor
  • Adequate cardiac function defined as left ventricular ejection fraction >40%, or shortening fraction ≥25%
  • EKG without evidence of clinically significant arrhythmia
  • Adequate renal function defined as creatinine clearance or radioisotope GFR 50 ml/min/1.73m2 (GFR 40 ml/min/1.73m2 if < 2 years of age)
  • Adequate pulmonary function defined as forced vital capacity (FVC) ≥50% of predicted value; or pulse oximetry ≥92% on room air if patient is unable to perform pulmonary function testing
  • Total Bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5 times the upper limit of normal for age
  • Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
  • For females of child bearing age:
  • Not lactating with intent to breastfeed; Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment; If sexually active, agreement to use birth control until 3 months after T-cell infusion. Male partners should use a condom
  • Available autologous transduced T-cells that has met GMP release criteria; Exclusion
  • Known primary immunodeficiency
  • History of HIV infection
  • Clinically significant active infection including fungal infection with ongoing antifungal therapy, viral infection or uncontrolled viral reactivation of EBV, CMV, Adv, BK-virus, or HHV-6
  • Receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone, in the 7 days prior to CD7-CAR T-cell infusion
  • Receiving systemic immunosuppressive therapy in the 14 days prior to CD7-CAR T-cell infusion that in the opinion of PI will interfere with the infused product
  • Active CNS disease
  • Known contraindication to the protocol defined lymphodepleting chemotherapy regimen of fludarabine/ cyclophosphamide
  • AML patients who failed FDA-approved targeted treatment options (e.g., FLT3 inhibitors, IDH1/IDH2 inhibitors, NPM1/KMT2A, CD33-directed agents). We define therapy failure as meeting one of the following:; contraindications to receiving targeted therapy; or; toxicities that necessitate stopping the targeted therapy; or; progressive disease

Helyszínek itt: Egyesült Államok

  • St. Jude Children's Research HospitalMemphis, Egyesült ÁllamokContact: Swati Naik, MBBSToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

Primary Objective:

A teljes eredeti leírásKevesebb

To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD7 negative T-cells expressing CD7-CARs (CD7-CAR T cells) in pediatric patients with recurrent/refractory CD7+ hematological malignancies after lymphodepleting chemotherapy.

Secondary Objectives:

To evaluate the antileukemic activity of CD7-CAR T cells. As a phase I study, efficacy is not the primary objective of this study, but remains an important outcome to evaluate. We will determine the anti-leukemic activity of the CD7-CAR T cells in the bone marrow and in the treatment of extramedullary disease.

A vizsgálat 2 csoportja

  • Arm AA vizsgált kezelés

    patients will receive autologous CD7-CAR T-cells

    Kezelés: Fludarabine, Cyclophosphamide, CliniMACS és Mesna

  • Arm BA vizsgált kezelés

    Patients will receive lymphodepleting chemotherapy (Cy/Flu), followed by an infusion of CD7-CAR T cells.

    Kezelés: CliniMACS

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. november 17.